Johnson & Johnson: Respiratory Syncytial Virus Infections trials

The registry lists 16 Respiratory Syncytial Virus Infections studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 1 6Phase 2 8Phase 3 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV InfectionCompletedNCT05070546Phase 3Results posted
• Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)TerminatedNCT04056611Phase 2Results posted
• Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus InfectionTerminatedNCT03656510Phase 2Results posted
• A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial VirusCompletedNCT03379675Phase 2Results posted
• An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old AdultsCompletedNCT03334695Phase 2Results posted
• A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus InfectionCompletedNCT03332459Phase 2Results posted
• Idylla IFV-RSV Panel Clinical TestingCompletedNCT02786381
• A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial VirusCompletedNCT02673476Phase 2
• A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) InfectionTerminatedNCT02593851Phase 1
• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult ParticipantsCompletedNCT02478333Phase 1
• Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.CompletedNCT02387606Phase 2
• A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176CompletedNCT02231671Phase 1
• A Study of ALS-008176 in Infants Hospitalized With RSVCompletedNCT02202356Phase 1
• A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge ModelCompletedNCT02094365Phase 2
• Study of Single and Multiple Doses of ALS-008176 in Healthy VolunteersCompletedNCT01906164Phase 1
• RV568 - Viral Challenge With RSVCompletedNCT01230645Phase 1